Sign In
Buy TCON
$0.0322
+0 (+0%)
At Close: Oct 15, 2025
TRACON Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
04:03pm, Tuesday, 10'th Nov 2020
SAN DIEGO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer
TRACON to Report Third Quarter 2020 Financial Results and Company Highlights on November 10, 2020
08:05am, Tuesday, 03'rd Nov 2020
SAN DIEGO, Nov. 03, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer
TRACON Announces FDA Orphan Drug Designation for TRC102 in Malignant Glioma, Including Glioblastoma
08:05am, Monday, 26'th Oct 2020
SAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer
